CD8A and melanoma: The timing of the melanoma growth control suggested the generation of an anti-cancer effector T cell response, therefore we analyzed CD8+ and CD4+ T cells present in the tumor-draining iLN (tdLN) (Fig. 5e-j and Additional file 1: Figure S4) and the grafted B16-OVA tumor (Fig. 5k-n and Additional file 1: Figure S5) 3 days after cDC1 administration (Fig. 5a).